Coronavirus Infections Clinical Trial
Official title:
Observational Program to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers Aged 18-65
NCT number | NCT05083039 |
Other study ID # | BV-PM-05/20 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 14, 2020 |
Est. completion date | September 3, 2021 |
Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19
Status | Completed |
Enrollment | 1500 |
Est. completion date | September 3, 2021 |
Est. primary completion date | December 14, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Volunteers must meet the following inclusion criteria: - Healthy volunteers aged 18-65 years. - The presence of a written and dated informed consent of the volunteer to participate in the program. - Consent to observe precautionary measures to limit the circulation of the vaccine virus among people around the vaccinated person (personal hygiene, isolation from unvaccinated children and people with immunodeficiency). - Volunteers who are able to fulfill the requirements of the protocol (i.e., fill out a self-observation diary, remember the dates of control visit). Non-inclusion criteria: - COVID-19 infection (including cases of asymptomatic carrier). - Positive test for COVID-19 (PCR). - Vaccination with any live and / or replicative vaccine one month before screening. - Neurological disorders that accompany previous vaccination with oral polio vaccine. - Immunodeficiency condition (primary). - Malignant neoplasms. - Immunosuppression (vaccinations are carried out no earlier than 3 months after the end of the course of therapy). - Pregnancy. - Hypersensitivity to any component of the vaccine. - Strong reaction (temperature above 40°C) or a complication on the previous administration of the drug. - Acute infectious or non-infectious diseases. Vaccinations are carried out 2-4 weeks after recovery or remission. In case of mild acute respiratory viral infections, acute intestinal diseases, vaccinations are carried out after the temperature normalizes. - The presence in the family or immediate environment (and provided that it is impossible to separate) of unvaccinated against polio (for example, newborns or children who have contraindications to polio vaccinations). - The presence of persons with immunodeficiency in the family or immediate environment (and provided that it is impossible to separate). Exclusion Criteria: - A volunteer can be excluded from the study under the following conditions: - Refusal of a volunteer to participate in the program. - The need for procedures and / or drug treatment that are not permitted by the protocol of this study. - The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol. - The appearance of non-inclusion criteria during the study. - Non-compliance with the research procedures by the volunteer. • Any condition of the volunteer that requires, in the reasonable opinion of the research doctor, the withdrawal of the volunteer from the study. - The volunteer is out of observation. • For administrative reasons |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Health of Russia | Kirov |
Lead Sponsor | Collaborator |
---|---|
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of detected cases | The number of detected cases confirmed by laboratory (PCR and / or serological tests). | within 12 months by groups |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04553575 -
CoViD-19 Patient in Reims University Hospital in March to April 2020
|
||
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Active, not recruiting |
NCT05548439 -
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
|
Phase 1 | |
Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05726084 -
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
|
Phase 2/Phase 3 | |
Recruiting |
NCT05069129 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
Recruiting |
NCT05599516 -
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
|
Phase 3 | |
Completed |
NCT05047900 -
The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community
|
N/A | |
Completed |
NCT04420286 -
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
|
||
Completed |
NCT04424355 -
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
|
||
Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
Enrolling by invitation |
NCT04327349 -
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
|
N/A | |
Completed |
NCT04321278 -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
|
Phase 3 | |
Recruiting |
NCT04327570 -
In-depth Immunological Investigation of COVID-19.
|
||
Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
Recruiting |
NCT04322344 -
Escin in Patients With Covid-19 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT04323592 -
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
|
||
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Active, not recruiting |
NCT04305457 -
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
|
Phase 2 |